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Abstract
This review considers the interaction of Complex I with different redox acceptors, mainly homologs and analogs of the
physiological acceptor, hydrophobic Coenzyme Q. After examining the physical properties of the different quinones and
their efficacy in restoring mitochondrial respiration, a survey ensues of the advantages and drawbacks of the quinones
commonly used in Complex I activity determination and of their kinetic properties. The available evidence is then displayed
on structure–activity relationships of various quinone compounds in terms of electron transfer activity and proton
translocation, and the present knowledge is discussed in terms of the nature of multiple quinone-binding sites in the
Complex. q 1998 Elsevier Science B.V.
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1. Introduction
Not only is Complex I the respiratory enzyme
having the most complicated structural organization,
but, in addition, there is no universally accepted and
reliable assay for its activity, mainly due to uncer-
tainty on the nature of the optimal quinone acceptor
to be used. Understanding the specificity of the en-
zyme for its quinone acceptor would not only shed
light on the functional mechanism of the complex,
but also contribute to standardize the enzymatic de-
termination. Owing to the alterations of Complex I in
w xsome mitochondrial disorders 1 and to its suggested
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w xinvolvement in some neurodegenerative diseases 2
w xand in aging 3 , an unambiguous definition of
quinone specificity in its assay is highly desirable.
This review summarizes present knowledge on the
interaction of Complex I with its redox acceptors.
2. Physical properties of Coenzyme Q homologs
 . Coenzyme Q CoQ or ubiquinone 2,3-di-
.methoxy-5-methyl-6-polyprenyl-1,4-benzoquinone is
the natural electron acceptor of Complex I from
eukaryotic sources. The side chain in the 6 position
of the benzoquinone ring ranges from 6 to 10 iso-
prenoid units, being CoQ common in yeasts, CoQ6 8
in some bacteria, and CoQ and CoQ in vertebrates9 10
w x4 .
Natural CoQ homologs are exceedingly hydropho-
w xbic molecules 5,6 so that they were postulated to be
located in the hydrophobic core of the lipid bilayer
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w x7 . Nevertheless, the precise localization and orienta-
tion of the CoQ molecule in artificial bilayers and
natural membranes has been the subject of consider-
w xable research 8–14 .
w xLinear dichroism studies in model systems 15,16
strongly support the concept that CoQ is located in
the lipid bilayer in a highly dynamic state, existing as
the time average of two limiting orientations, one
with the benzoquinone ring in the bilayer midplane
and lying parallel to the membrane surface, and the
other with the ring parallel to the lipid acyl chains
near the polar heads, such that the benzoquinone ring
with the first couple of isoprenoid units oscillates
w xbetween the two limit positions 17,18 . In a recent
w xstudy 19 employing molecular dynamics simulation
and energy minimization of CoQ homologs, a folded
structure was achieved for long chain homologs
 .CoQ to CoQ , where the last isoprenoid unit is in6 10
close contact with the benzoquinone ring. The geom-
etry of the molecules thus obtained allowed to calcu-
late theoretical diffusion coefficients according to the
w xfree volume theory 20 ; the values in the range of
10y7 cm2 sy1 are strikingly in accordance with the
high diffusion coefficients of natural quinones experi-
mentally found by fluorescence quenching of mem-
w xbrane probes 18,21–23 . EPR studies of the radical
anions and cations of CoQ and CoQ , together with6 10
w xmolecular orbital calculations 24 also yielded a
folded conformation as the one having the minimum
free energy.
w xAn aliquot of CoQ is protein-bound 25–29 , but
its significance, whether representing a fixed coenzy-
matic form of the CoQ-reactive enzymes or merely
substrate binding in the active site, is not completely
w xclarified 30 . Protein binding is required to stabilize
w xthe semiquinone form in the Q-cycle 31–33 ; in
Complex III, whose crystalline X-ray structure has
w xbeen recently solved 34,35 , only one molecule of
bound ubiquinone, out of the two to three molecules
w xpredicted by functional models 32,33,36–38 has
w xbeen observed 34 . In Complex I, one molecule of
w xubiquinone might be firmly bound 39 , in analogy
with Q of the reaction center of photosyntheticA
w xbacteria 40 , whereas another molecule could be in
equilibrium with the quinone pool, in analogy with
Q .B
Being natural ubiquinones extremely hydrophobic
molecules, a series of homologs and analogs having
Table 1
Partition coefficients of some quinones used as Complex I accep-
tors
Quinone log P cyclohexanerwater log P membranerwater
CoQ 0.39 y0
DQ 2.45 y
CoQ 2.65 2.91
PB 3.7 3.6
CoQ 5.1 4.02
DB 7.2 4.7
CoQ 7.7 4.83
UBQ 8.0 y
shorter chains in the 6 position are used as substrates
w xfor Complex I assays 41 . These quinones have finite
w xmembranerwater partition coefficients 42 , that have
to be taken into account in any consideration con-
cerning their specificity and kinetics of interaction.
The cyclohexanerwater partition coefficients of
different quinones are good parameters of their hy-
drophobicities and are known from the literature
w x  .43,44 Table 1 . Membranerwater partition coeffi-
cients can be determined indirectly, e.g., by fluores-
cence quenching by the quinones of fluorescent probes
w xinserted in the m em brane 45,46 . The
membranerwater partition coefficients of CoQ and1
 .pentyl-ubiquinone PB , determined by fluorescence
quenching, agree with the cyclohexanerwater corre-
sponding values, but more hydrophobic quinones are
w xunderevaluated 42 because their partition from wa-
ter to the membrane competes with their micelliza-
w xtion in water 21 . The fluorescence quenching-de-
rived coefficients are valuable because they reflect
the incorporation of the quinones in the membrane
under usual experimental conditions.
An additional consequence of the high hydropho-
bicity of ubiquinones, related to their partition coeffi-
w xcients, is their solubility in monomeric state 21,47 ;
only quinones with very short chains as CoQ or1
.PB are monomeric in the concentration ranges used
in Complex I assays, whereas already CoQ and2
 .decyl-ubiquinone DB form micelles at or below
micromolar concentrations in the assay medium. If
the micelle-to-monomer transition is rate-limiting with
respect to the enzymatic kinetic steps, then any rate
determination would become meaningless.
Water insolubility is particularly serious a phe-
nomenon for oxidized quinones, as in Complex I
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activity determination, since the hydroquinone forms,
used in Complex III activity determination, are signif-
w xicantly less hydrophobic 6,48,49 .
An important consideration concerning the use of
ubiquinones as substrates is their reaction with the
partner enzymes from within the lipid bilayer: in
most cases the kinetic constants of these enzymes are
calculated taking into account the total substrate con-
centration in the heterogeneous assay mixture, rather
than the true substrate concentration in the mem-
brane. This can lead to ambiguity when performing
comparisons of the specificity of substrates having
different partition coefficients. Some investigators
have developed enzyme kinetics in two-phase sys-
w xtems 50–54 ; a method to determine the true mem-
brane K and the partition coefficients was describedm
for ubiquinols in ubiquinol cytochrome c reductase
by steady-state kinetic measurements at varying
phospholipid fractional values in the assay medium
w x53 . Alternatively, knowing the partition coefficient,
the true membrane concentration of the substrate and
hence the true K and other kinetic constants can bem
w xderived 42 .
3. Kinetics of the Coenzyme Q pool
The isolation of four discrete lipoprotein redox
complexes from the inner mitochondrial membrane
w x55 and the finding that the respiratory chain could
w xbe reconstituted from the isolated complexes 56,57
w xled Green and Tzagoloff 57 to postulate that overall
respiratory activity is the result of intercomplex elec-
tron transfer ensured by rapid diffusion of mobile
components acting as cosubstrates, i.e., CoQ and
cytochrome c. In the subsequent years the organiza-
tion of the respiratory chain was enriched of an
w xincreased number of respiratory complexes 58 . A
Random Collision Model was systematically elabo-
w x w xrated by Hackenbrock 59 , Schneider et al. 60 , and
w xHackenbrock et al. 61 , who provided convincing
evidence that the respiratory chain components un-
dergo independent lateral diffusion, so that electron
transfer is a diffusion-coupled kinetic process. Hack-
enbrock also postulated that electron transfer is rate-
limited by the diffusion of the fastest components
 . w xCoQ and cytochrome c 61 ; this latter proposal has
w xbeen questioned by our group 18,21,23,30 .
The first detailed kinetic analysis of the redox
reactions involving CoQ in the respiratory chain was
w xelaborated by Kroger and Klingenberg 62,63 , who¨
showed that steady-state respiration could be mod-
elled as a single two-enzyme system, the first causing
reduction of CoQ and the second causing oxidation
of ubiquinol; the overall flux is determined by the
redox state of the quinone and hence is a hyperbolic
function of the rates of quinone reduction and reoxi-
dation, according to the well known pool equation
 w xcf. Refs. 64,65 . The pool behavior allows to calcu-
late one unknown or uncertain parameter if the other
two parameters are known the three parameters be-
ing overall rate of respiration, rate of quinone reduc-
.tion and rate of its reoxidation . This procedure has
been useful for determining the rate of Complex I
activity indirectly when its direct determination had
been found unreliable for the unsuitability of the
w xquinone acceptors 66 .
If the CoQ concentration in the membrane is not
saturating for the activity of reducing and oxidizing
enzymes, the pool equation is modified by feeding it
into the Michaelis–Menten equation for enzyme ki-
w xnetics 65,67 , taking into account the total CoQ
w xconcentration, Q , the individual maximal velocitiest
of the enzymes reducing and reoxidizing the CoQ
pool, and their dissociation constants for ubiquinone;
w xthe rate of respiration is hyperbolically related to Qt
and maximal turnovers of electron transfer are at-
w xtained only at Q saturating both CoQ reduction andt
reoxidation.
Direct titrations of lyophilized beef heart mito-
chondria depleted of their CoQ complement and re-
constituted with different CoQ supplementations
yielded a K of NADH oxidation for Q in the rangem t
y1 w xof 2–5 nmol mg mitochondrial protein 68,69 ;
considering a phospholipid content of 0.5 mg mgy1
w x w xprotein 70 , this value corresponds to a Q of 4–10t
w xmM in the lipid bilayer 69,71 . This K value ism
practically important in defining the hyperbolic rela-
tion between membrane CoQ concentration and elec-
w xtron transfer rate 69 . Analysis of the literature
w x4,72,73 shows that the physiological CoQ content of
several types of mitochondria is in the range of the
K for NADH oxidation, and therefore not saturatingm
for this activity.
In contrast to NADH oxidation, the K values ofm
w xsuccinate 69 and of glycerol-3-phosphate oxidation
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w x74 for CoQ were found to be one order of magni-
tude lower; since in all cases CoQ, once reduced, is
reoxidized by Complex III, and since the rates of
oxidation, at least of NADH and succinate, do not
w xdiffer to large extents 64 , it follows that the high
K for CoQ of aerobic NADH oxidation must be am
reflection of a correspondingly high K of Complexm
I for the quinone. This lower affinity of the CoQ-bi-
nding sites in Complex I with respect to the other
mitochondrial CoQ-binding enzymes may indicate
some unique structural feature of this site.
A consequence of such low affinity for CoQ is the
rate enhancement of NADH cytochrome c reductase
upon CoQ incorporation by cosonication of the10
quinone with bovine heart submitochondrial particles
 .SMP : NADH oxidation, but not succinate oxida-
tion, was almost doubled when CoQ was incorpo-10
w xrated 75 . This finding argues against a possible
artifactual decrease of quinone affinity for Complex I
due to the lyophilization and solvent extraction pro-
cedures used in the reconstitution experiments.
The implications of a ‘high’ K of Complex I form
CoQ are worth considering, since a deficiency of
CoQ, not corrected by sufficient biosynthesis, was
postulated to occur in different kinds of human
w xpathologies 76,77 .
Although the CoQ content can be raised in vitro in
the inner mitochondrial membrane above the physio-
logical level and close to kinetic saturation, in vivo
experiments have failed to indicate a mitochondrial
CoQ increase when the quinone was administered by
w x w xperfusion 78 or dietary means 79,80 . This failure
does not appear to be due to an upper limit of
solubility of long-chain ubiquinones in the membrane
w xphospholipids 75 .
4. Quinone specificity in NADH oxidation
In their early extraction–reconstitution studies,
w xLenaz et al. 81 first reported that succinate oxidase
is not very specific in the structural and steric re-
quirements for the isoprenoid side chain, whereas
NADH oxidase is rather specific, being reactivated
only by CoQ homologs having long isoprenoid side
 .chains )6 units . Since CoQ reduced by either
enzyme is reoxidized by Complex III, the specific
requirements of NADH oxidation must be referred to
properties in the Complex I active site. Accordingly,
CoQ homologs having short isoprenoid chains like
.CoQ and CoQ inhibit NADH oxidation competi-2 3
w xtively with long-chain homologs 42,82 . Although
the inhibitory action is well documented, no rigorous
study has yet excluded the possibility that inhibition
is exerted by contaminating impurities of the
quinones.
The difference in specificity of the isoprenoid side
chain of CoQ in restoring NADH oxidase and succi-
nate oxidase activities of CoQ-depleted mitochondria
led to the formulation of the existence of two steri-
cally different sites for CoQ in NADH CoQ reductase
w xand succinate CoQ reductase 75,81 , having different
sensitivities to the lipoidal and steric nature of the
isoprenoid side chain, as also indicated by the differ-
ent specificity of the two enzymes for the quinones as
 .acceptors Section 5 and by the different sensitivity
w xto CoQ competitive inhibitors 83 .
It was subsequently found that the saturated chain
analog DB was as active as CoQ in restoring10
w xNADH oxidation 75 , in agreement with its high
w x  .acceptor activity 42 cf. Section 5 . A practical
consequence of these findings is that low or interme-
diate CoQ homologs are unlikely to restore respira-
tory chain deficient activities under pathological con-
ditions, whilst the low analog DB would represent an
interesting candidate for inserting an effective quinone
w xin intact tissues 75 . The hydroxydecyl analog
idebenone, used in clinics to correct respiratory chain
w xdeficiencies 84–86 , is however a potent respiratory
w xchain inhibitor at the level of Complex I 87 , making
its therapeutical use of questionable efficacy.
5. A survey of routinely used quinones as complex
I acceptors
From hence on, I will define the site in Complex I
where the natural CoQ from the pool is reduced as
the ‘physiological site’, whereas any other site in the
enzyme where exogenous quinones or other com-
pounds can accept electrons will be considered ‘non-
physiological’.
w xAmong the oxidants used, ferricyanide 88 accepts
electrons prior to the physiological reduction site, as
shown by the lack of inhibition by rotenone of NADH
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w xferricyanide reductase 89 and by retention of NADH
ferricyanide reduction activity in the solubilized type
w xI NADH dehydrogenases 90 lacking the hydropho-
bic sector of the enzyme. Other oxidants are reduced
by Complex I in a rotenone-insensitive pathway, such
 . w xas hexammineruthenium III 91 and a series of
w xquinones and nitro-compounds 92 but their kinetic
mechanism of reduction is different from that of
w xferricyanide. Degli Esposti et al. 93 , investigating
the rotenone-insensitive component of reduction by
Complex I of Coenzyme Q analogs differing in the
substituents in the 6 position, provided evidence for
the existence of a rotenone-insensitive, nonphysiolog-
ical site for the most hydrophilic quinones, in addi-
tion to two different rotenone-sensitive quinone-bind-
 .ing sites cf. Section 7 . Moreover the reduction of
such oxidants as ferricyanide, Wurster’s Blue, and
 .2,6-dichlorophenol-indophenol DCIP is not coupled
w xto energy transduction 94 .
The electron acceptors most commonly employed
as substitutes of the physiological ubiquinones are
w xCoQ homologs and analogs 41,95 . It is assumed
that these compounds interact with the physiological
 .site s , in place of the endogenous CoQ, by first
partitioning from the water phase to the membrane
and that exogenous quinones are reduced directly by
Complex I, without the mediation of the ubiquinone
w xpool 42,53,96 . The discovery that the enzyme con-
w xtains bound ubiquinone essential for its activity 97
reopens the question of the mode of interaction of
 . exogenous quinones with the acceptor site s Section
.8 .
Among the quinone acceptors used are the ho-
w xmolog series from CoQ up 41,95 , including less0
frequently long isoprenoid chain homologs in spite of
w xtheir insolubility in water 89 , the tetramethyl benzo-
 .quinone analog, duroquinone DQ , and analogs hav-
ing straight saturated chains such as 6-pentyl, 6-decyl
and 6-undecyl ubiquinones usually abbreviated as
.PB, DB, and UBQ, respectively . Among these, the
most commonly used in the assay of Complex I have
w xbeen CoQ and DB; however, CoQ 94 , CoQ1 0 2
w x w x w x27,98 , PB 42,83,99 , and UBQ 100,101 have also
been employed.
The suitability of many of these commonly used
w xacceptors has been questioned 102 ; the main reason
has been the observation that NADH CoQ reductase
activity, as experimentally determined, is often para-
doxically found lower than NADH cytochrome c
w xreductase or NADH oxidase 66,103 .
The reasons for underevaluating the reduction of
exogenous quinones by NADH may be summarized
as follows.
 .a The water solubility of the quinones with re-
spect to their K is fundamental for assessing thatm
 .kinetic saturation is reached during assay Section 2 .
 .b Some quinones, as CoQ , are significantly0
reduced in a rotenone-insensitive fashion, indicating
that they accept electrons from a site situated up-
stream from the flow into the hydrophobic moiety of
the enzyme, thus sharing in part the behavior of
water-soluble oxidants such as ferricyanide. Degli
w xEsposti et al. 93 , in a detailed study of the speci-
ficity of quinones differing in their side chain compo-
sition, found that compounds eliciting highly
rotenone-insensitive activities were clustered in two
classes having different hydrophobicities.
In beef heart mitochondria or SMP, both CoQ and1
 .DB exhibited high rotenone sensitivity )90%
w x w x42,93 ; however, even in beef heart SMP 104 and
w xin purified Complex I from bovine heart 105 , a high
rotenone-insensitive rate with CoQ was found in1
absence of added phospholipids, but significant only
at high quinone concentrations. Using CoQ , the1
rotenone sensitivity was about 80% in non-synaptic
w xmitochondria from rat brain cortex 106 , but only
w x0–30% in rat liver mitochondria 103 and in human
w xplatelets mitochondria 107 . DB reduction exhibited
higher rotenone sensitivity, i.e., )90% in both brain
and liver mitochondria quoted above, whereas it was
w x70–80% in platelet mitochondria 107 ; in the latter,
it was reported that UBQ reduction is over 90%
w xinhibited by rotenone 100 .
 .c The respiratory chain contains quinone reduc-
w xtion sites in Complex III 108–111 , where exoge-
nous quinones may accept electrons in addition to or
 .in competition with the natural site s in Complex I.
The use of Complex III inhibitors to avoid reduction
downstream the dehydrogenase may involve addi-
tional problems, since some of the so-called center o
w xinhibitors of Complex III 32 , as myxothiazol, also
w xinhibit Complex I 112 . The additive inhibition of
w xquinone reduction 42 by antimycin A and mucidin
w x113 demonstrates that both centers i and o behave
as quinone reduction sites in Complex III when
NADH is the electron donor.
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By far the quinone which is mostly reduced at
 .  .center i is duroquinone DQ ca. 50% , whereas
CoQ and DB are usually least affected by antimycin1
w x42 . The preferential reduction of DQ by Complex
III with respect to Complex I or even more Complex
w x.II 108,109 is not due to thermodynamic reasons, as
the midpoint potential of the DQrDQH couple is2
slightly lower than that of ubiquinonerubiquinol
w x114 ; thus it must depend on the extent to which the
exogenous quinone competes with endogenous CoQ10
w xfor the reduction site in the dehydrogenase 42,115 :
if the exogenous quinone competes strongly with
CoQ , then it is preferentially reduced by the dehy-10
drogenase; otherwise the electrons are transferred to
Complex III by the endogenous pool and find addi-
tional reduction sites for the exogenous acceptor
w x42,116 . Poor acceptors from Complex I, such as
DQ, would compete such that 50% of the electrons
still reach Complex III through the pool.
 .d Some quinones are Complex I inhibitors. The
inhibitory action of CoQ and other short chain2
 .isoprenoid homologs but not of CoQ , well docu-1
w xmented in beef heart mitochondria 42,81,82 , was
also observed in human lymphoblast mitochondria
w x117 ; moreover, CoQ was shown to inhibit cell2
w xgrowth in culture 118 . As pointed out in Section 4,
clinically used idebenone also inhibits Complex I
w x87 .
6. Kinetics of quinone reduction
In bovine heart SMP only CoQ and DB were1
found to elicit rates comparable to those calculated
for reduction of endogenous CoQ using the pool10
w xequation 71 , and their reduction was almost com-
pletely inhibited by rotenone and only marginally
w xaffected by Complex III center i inhibitors 42 .
Using CoQ , as well as other acceptors, NADH1
CoQ reductase follows a ping-pong kinetic mecha-
nism, whereby the enzyme is first reduced by aque-
ous NADH with release of NADq and then reoxi-
dized by ubiquinone with release of ubiquinol in the
w xlipid phase 42 . The overall turnover number of the
 .enzyme two electrons from NADH to CoQ calcu-
lated on the basis of Complex I content of SMP,
approached 500 sy1, close to that found for DCIP
w xreduction 115 .
The parameter k rK , the minimum second-ordercat m
association rate constant of an enzyme with a sub-
 . w xstrate k 119 , is one order of magnitude highermin
for DB than for CoQ , due to the low K of the1 m
w xenzyme for the former compound 42 ; however,
calculation of the effective quinone concentration in
the lipid phase, which is a function of the partition
w x  .coefficient 53 Section 2 , shows that CoQ is a1
better substrate than DB, with a k of 4.3=104min
My1 sy1, to be compared with 1.9=103 My1 sy1
for DB; the k for CoQ is close to the value thatmin 1
 4 y1 y1.can be calculated for CoQ 8.8=10 M s10
 w x.cf. Ref. 42 . Table 2 summarizes the kinetic prop-
erties of a series of quinones as Complex I acceptors.
The relatively low value of the true k rK forcat m
CoQ which approaches k , the association rate1 5
.constant of CoQ with the enzyme and the high1
activation energy of the same parameter derived from
w xArrhenius plots 42 suggest that NADH CoQ reduc-1
tase activity is not diffusion-limited. The close value
Table 2
a w xKinetic constants of NADH–CoQ reductase in bovine heart SMP using various acceptors 42
y1 y1 y1 y1 y1 .  .  .  .  .  .  .  .  .k s K Q in water mM K Q in lipids mM k Q in water mM s k Q in lipids mM scat m m min min
CoQ 70 65 y 1.1 y0
CoQ 380 20.1 8.9 18.9 431
CoQ 112 1.3 36 86 3.12
CoQ 66 0.8 61 82.5 1.13
PB 360 21.0 98 17.1 3.7
DB 225 1.8 138 125 1.6
b bCoQ 441 5 8810
aData were obtained from titrations at variable quinone concentrations, keeping NADH concentration at 75 mM. Thus, k are slightlycat
w x  .  .lower than those obtained from secondary kinetic plots 42 . K Q and k Q in the lipid phase were calculated using the partitionm min
 .coefficient cyclohexanerwater from Table 1.
b w xCf. Ref. 42 for discussion.
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of the k rK ratio for CoQ with respect to CoQcat m 10 1
allows us to suggest that also the physiological activ-
ity with the natural acceptor is not diffusion-limited,
similarly to what found for ubiquinol cytochrome c
w xreductase 71 .
7. Structure–activity relationships and the nature
of the quinone-binding sites
Evidence that Complex I contains multiple
quinone-binding sites was largely collected by studies
 .with inhibitors cf. Degli Esposti in this issue . Most
models of proton translocation by Complex I take in
account the existence of at least two quinone sites
w x27,39,120–123 ; these postulated sites are physio-
logical by definition, being involved in the natural
mechanism of energy conservation. In addition, ex-
tensive evidence demonstrates the existence of a non-
physiological site, capable of reducing quinones and
other oxidants. This site seems different from the
w xferricyanide site 91,92 for its kinetic properties. The
reduction of soluble quinones, including CoQ , by1
w xisolated Complex I 92 is less sensitive to the action
of inhibitors of the CoQ-binding site, in comparison
w xto that of SMP 88 ; this may be determined by the
w xdiminished phospholipid to protein ratio 105 , since
phospholipids appear to increase the affinity of
w xquinones to the rotenone-sensitive site 105 . In iso-
lated Complex I, the rotenone-insensitive site has
higher turnover and lower k , whereas themin
rotenone-sensitive site has lower turnover and higher
w xk 92 . Quinones at this site are largely reduced bymin
a one-electron mechanism, as shown by the depen-
dence of the log k on their one-electron reductionmin
potentials.
The stoichiometry of electron transfer from NADH
to CoQ approaches 1 for many straight chain quinones
but is approximately 0.5 with CoQ or with idebenone2
w x87 , indicating that they are incompletely reduced,
presumably at the expense of molecular oxygen, as
demonstrated by the antimycin-insensitive, superox-
ide dismutase-sensitive reduction of cytochrome c,
similar to naphthoquinones and other quinones which
stimulate a rotenone-insensitive oxidation of NADH
w x92,124 . Since CoQ reduction is more sensitive to2
rolliniastatin-2 and rotenone than idebenone reduc-
w xtion 87 , it was concluded that idebenone reacts with
a site upstream to the action of inhibitors, possibly
iron–sulfur centers, whereas CoQ interacts with a2
site downstream the action of inhibitors. The instabil-
ity of the enzyme-bound quinone intermediates was
taken as the mechanism of inhibition of the enzyme
w x87 . Some other more specific mechanism must ex-
ist, however, to explain why CoQ inhibits NADH2
oxidation, whereas other quinones, which also pre-
w xsumably react with oxygen 92 , acti˝ate electron
w xtransfer from NADH. The study by Fato et al. 42
revealed that the K of CoQ as a competitive in-i 2
hibitor was identical to its K as an acceptor sub-m
strate and that the inhibitory form was presumably
the reduced quinone. On the other hand the analog
DB, which differs from CoQ only for having a decyl2
saturated rather than a diprenyl side chain of ten
carbon atoms, was not an inhibitor at all. The differ-
ence in V , but not in K , between the two accep-max m
tors suggests that the isoprenoid chain of CoQ is not2
correctly positioned at the active site for optimal
electron transfer. The same type of hindrance is
expected for all isoprenoid quinones having side
chains between two and five units, as they all are
unable to restore NADH cytochrome c reductase
w xactivity 81 . The inhibition by short isoprenoid chain
quinones is a peculiar character of Complex I, not
w xshared by either Complex II 125 or Complex III
w x49,71,126 . Any explanation of the inhibitory action
of short chain isoprenoid homologs has to explain the
lack of inhibition of the corresponding saturated chain
analogs.
Also the different rotenone sensitivity of the direct
w xand reverse reaction catalyzed by Complex I 127 in
w xthe active or pulsed state 128 was ascribed to the
existence of two different sites, one for ubiquinone
and the other for ubiquinol binding, having different
rotenone sensitivities.
The Arg340 “His mutation occurring in subunit
ND4 of the Complex in the ND4r11778 form of
Leber’s hereditary optic neuropathy is accompanied
by an increased K for CoQ and by a decreasedm 2
rotenone sensitivity in platelet mitochondria
w x100,129 ; the decreased stability of an ubisemi-
quinone intermediate, due to replacement of the basic
arginine residue with a less basic histidine, would be
responsible for the decrease of affinity for both the
w xacceptor CoQ and the inhibitor rotenone 100 . If the2
affinity for the natural acceptor, CoQ , is also de-10
(
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Table 3
Synopsis of some properties of quinones as electron acceptors of Complex I
aQuinone Properties Reference Comment
Isolated Complex I
w xCoQ Amytal-insensitive 142 Nonphysiological site0
w xHigh rotenone-insensitive rate 105
w xCoQ High activity, 100% amytal- and rotenone-sensitive, K higher than in situ 89,142 Physiological site1 m
y w xOnly partial rotenone sensitivity, partly 1e 92 Two sites
w xPartial rotenone sensitivity, increased by PL 105 Two sites
w xCoQ Low activity, amytal-sensitive 142 Poor acceptor at physiological site2
w xCoQ Low activity 89 Water insoluble6
w xCoQ Low activity 4,89 Water insoluble10
w xPB High rotenone sensitivity 105 Physiological site
w xDB High rotenone sensitivity 105 Physiological site
b y w xBQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
w x2,3-dimethoxy-5,6-dimethyl-BQ Amytal-insensitive 142 Nonphysiological site
y w x2,5-dimethyl-BQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
y w x2-methyl-BQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
c y w xNQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
y . w x2-methyl-NQ menadione Rotenone-insensitive, partly 1e 89,92,142 Nonphysiological site
y w x5,8-dioxy-NQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
y w x5-oxy-NQ Rotenone-insensitive, partly 1e 92 Nonphysiological site
y w x9,10-phenanthrene quinone Rotenone-insensitive, partly 1e 92 Nonphysiological site
y w xAdriamycin Rotenone-insensitive, partly 1e 92 Nonphysiological site
 . w x5-hydroxy-NQ Juglone High activity, piericidin-insensitive 88 Nonphysiological site
dBeef heart SMP
y w xCoQ High rate, )90% rotenone-sensitive, high Pr2e 104 Physiological site0
q y w x;50% rotenone sensitivity, low H r2e 141 Two sites
w xLow rate, 68% piericidin-sensitive 88 Two sites
w xLow rate, low rotenone sensitivity 42 Two sites
w xLow rate, low Dc and DpH generation 93,133 Two sites
y w xCoQ High rate, )90% rotenone-sensitive, high Pr2e 104,140 Physiological site1
q y w xHigh rotenone sensitivity, high H r2e 141 Physiological site
w xHigh rate, high piericidin sensitivity 88 Physiological site
w xHigh rate, high rotenone sensitivity, highest k 42 Physiological sitemin
w xHigh rate, high rotenone sensitivity, low Dc and DpH generation 93,133 Dual site
(
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y w xCoQ Low rate, )90% rotenone-sensitive, high Pr2e 104,140 Poor acceptor at physiological site2
w xLow rate, high piericidin sensitivity 88 Poor acceptor at physiological site
w xLow rate, high rotenone sensitivity, inhibitor 42 Poor acceptor at physiological site
w xLow rate, relatively low rotenone sensitivity, inhibitor 87,93,133 Dual sites, O reactivity2
w xCoQ Low rate, high rotenone sensitivity 42 Little solubility3
w xLow rate 93
w x6-methyl-CoQ High rate, high rotenone sensitivity, low DpH generation 93 Dual site
w x6-propyl-CoQ High rate, high rotenone sensitivity, low Dc and DpH generation 93,133 Dual site
w x6-propenyl-CoQ Intermediate rate, high rotenone sensitivity, low Dc and DpH generation 93,133 Dual site
 . w x6-butenyl-CoQ 2 isomers High rate, high rotenone sensitivity 93
 . y w x6-pentyl-CoQ PB High rate, 95% rotenone sensitivity, high Pr2e 140 Physiological site
w xHigh rate, high rotenone sensitivity, low k 43 Physiological sitemin
w xHigh rate, high rotenone sensitivity, high Dc and DpH generation 93,133 Dual site
w xHigh activity 131
w x6-hexyl-CoQ High rate, high rotenone sensitivity, high Dc and good DpH generation 93,133 Mainly physiological site
X X . w x6 2 4 -hexadienyl -CoQ Low rate, low rotenone sensitivity, relatively low Dc generation 93 Dual site
X X X6 1-methyl-2 ,4 -penta-
. w xdienyl CoQ Low rate, low rotenone sensitivity 93 Dual site
w x5-desmethyl-6-hexyl-CoQ Activity higher than PB 131
5-desmethyl-6- 1-methyl-
. w xpentyl CoQ As active as PB 131
5-desmethyl-6 2-methyl-
. w xpentyl CoQ Activity higher than PB 131
5-desmethyl-6- 3-methyl-
. w xpentyl CoQ Activity lower than PB 131
5-desmethyl-6- 4-methyl-
. w xpentyl CoQ Activity lower than PB 131
5-desmethyl-6- 1-ethyl-
. w xbutyl CoQ Activity slightly lower than PB 131
w x6-heptyl-CoQ Intermediate rate, high rotenone sensitivity, high Dc and DpH generation 93,133 Physiological site
6-octyl-CoQ Low rate, relatively low rotenone sensitivity,
q w xhigh Dc generation, inhibits H pumping 93,133 Inhibitor
w x6-nonyl-CoQ Intermediate rate, high rotenone sensitivity, high Dc and DpH generation 93,133 Physiological site
y . w x6-decyl-CoQ DB High rate, 100% rotenone-sensitive, high Pr2e 140 Physiological site
w xHigh rate, high rotenone sensitivity, low k 42 Physiological sitemin
 .but less efficient than CoQ1
w xHigh rate, high rotenone sensitivity, high Dc and DpH generation 93,133 Physiological site
w xHigh rate 131
(
)
G
.Lenazr
Biochim
ica
etBiophysica
Acta
1364
1998
207
–221
216 .Table 3 continued
aQuinone Properties Reference Comment
w x3-ethoxy-DB Same rate as DB 131
w x2-ethoxy-DB Rate lower than DB 131
w x2,3-diethoxy-DB Rate lower than DB 131
 . w x6-undecyl-CoQ UBQ High rate, high rotenone sensitivity, high Dc and DpH generation 93,133 Physiological site
 . w x6-hydroxydecyl-CoQ idebenone Low rate, low rotenone sensitivity, inhibits electron transfer and Dc 87 Inhibitor
w xBQ Low rate, low piericidin sensitivity 88 Poor acceptor at nonphysiological site
w x2-methyl-BQ Low rate, low piericidin sensitivity 88 Poor acceptor at nonphysiological site
w x2,3-dimethyl-BQ Low rate 88 Poor acceptor
w x2,5-dimethyl-BQ Low rate 88 Poor acceptor
w x2,6-dimethyl-BQ Low rate 88 Poor acceptor
w x2,3,5-trimethyl-BQ Low rate, high piericidin sensitivity 88 Poor acceptor
 . q y w x2,3,5,6-tetramethyl-BQ DQ Low rotenone sensitivity, low H r2e 141 Nonphysiological site
w xLow rate, high piericidin sensitivity 88 Poor acceptor
w xLow rate, high rotenone sensitivity, high reduction from Complex III 42 Poor acceptor
w x2,5-dimethoxy-3,6-dimethyl-BQ Low rate, high piericidin sensitivity 88 Poor acceptor
w x2,6-dimethoxy-3,5-dimethyl-BQ Low rate, high piericidin sensitivity 88 Poor acceptor
2,3-dimethoxy-5-methyl-6-
w xchloro-BQ High rate, 57% piericidin-sensitive 88 Two sites
2,3-dimethoxy-5-methyl-6-
w xbromo-BQ High rate, 50% piericidin-sensitive 88 Two sites
2-methoxy-3-hydroxy-5-methyl-
w x6-chloro-BQ Very low rate, 35% piericidin-sensitive 88 Poor acceptor
w x2,3-dichloro-5-methyl-BQ Very low activity, piericidin-insensitive 88 Poor acceptor
w x2,3-dichloro-5,6-dicyano-BQ Low activity, piericidin-insensitive 88 Poor acceptor
w x2,5-dihydroxy-BQ No activity 88
b w xNQ Low rate, 37% piericidin sensitivity 88
w x1,2-NQ High rate, piericidin-insensitive 88 Nonphysiological site
y . w x2-methyl-NQ menadione Low rate, low rotenone sensitivity, low Pr2e 104 Nonphysiological site
w xLow rate, 73% piericidin-sensitive 88 Two sites
w x5-hydroxy-NQ Low rate, low piericidin sensitivity 88 Nonphysiological site
w x2-hydroxy-NQ No activity 88
w x2-hydroxy-3-methyl-NQ No activity 88
w xAnthraquinone derivatives No activity 88
w xDoxorubicin High rotenone-insensitive reduction and O radical formation 143 Redox cycling2
w xDaunorubicin As above 143
w x5-imino-daunorubicin Low rotenone-insensitive reduction 143
a  .‘Nonphysiological’ refers to interaction with Fe–S clusters in the Complex; ‘physiological’ refers to rotenone-sensitive site s without further specification; ‘two sites’
w xmeans both physiological and nonphysiological; ‘dual site’ refers to the dual nature of the rotenone-sensitive site according to Refs. 93,133 .
bBQs1,4-benzoquinone.
cNQs1,4-naphthoquinone.
d w xRat liver mitochondria in Ref. 141 .
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creased, this could provide an explanation why the
rate of integrated electron transfer is decreased,
whereas NADH CoQ reductase activity is retained
w x130 . An alternative explanation would be if the
unstable ubisemiquinone reacted with oxygen, estab-
lishing a short-circuit of electron transfer regenerat-
w xing ubiquinone 100 and preventing reoxidation of
ubiquinol by the respiratory chain.
The decrease of rotenone sensitivity of Complex I
w xactivity observed in aging 106,107 might be related
either to specific changes of the CoQ-binding site, as
w xin Leber’s disease 100 , or, alternatively, to modified
assembly of the complex due to changes in the lipid
 w x.environment cf. Ref. 105 , or also to changes in the
proportion of resting and active forms of the enzyme
w x127 .
w xSakamoto et al. 131 observed that the
quinone-binding site of Complex I from beef heart,
contrary to that in Escherichia coli glucose dehydro-
genase, is not stringent in its specificity of sub-
stituents in the benzoquinone ring, and concluded that
the site is spacious enough to accommodate a large
variety of quinone compounds; in particular, substitu-
tion of the methoxy groups at position 2 and 3 with
ethoxy groups or removal of the methyl group at
position 5 did not affect reductase activity in a signif-
icant way. This lack of specificity reminds the prop-
w xerties of the quinol binding site in Complex III 132 ,
at difference with the high specificity of Complex II
w xfor the benzoquinone ring substituents 132 . The low
specificity of Complex I for the quinone ring sub-
stituents agrees with the substantial activity of the
2-amino-derivative rhodoquinone in NADH oxidation
 . w xbut not in succinate oxidation 81 .
w xSakamoto et al. 131 also studied the effect of the
structural changes in a six-atom side chain at position
6, and also found no specific requirement for Com-
plex I activity. In view of these findings, the inhibi-
w xtion by CoQ 42 and other analogs of similar size2
w x87,93 is even more puzzling. Studying the effect of
structural changes in side chains having 10 or more
carbon atoms might shed light on the mechanism of
inhibition.
w xDegli Esposti et al. 93 and Helfenbaum et al.
w x133 performed a detailed study of the specificity of
six-substituents on for NADH CoQ reductase activity
of beef heart SMP, investigating the rates of electron
transfer, the generation of membrane potential, and
proton translocation elicited by Complex I activity.
CoQ analogs with a saturated substituent of 1 to 3
carbons have the fastest rates of electron transfer
activity, and analogs with substituents of 7 and 9
carbons have the highest association rate constants, as
w xdefined by the k rK ratios 93 ; these ratios arecat m
not very sensitive to hydrophobicity as defined by the
cyclohexanerwater partition coefficients, contrary to
w xComplex III 49 ; this means that the true association
rate constants, corrected for the partition coefficient
in the membrane, actually decrease with increasing
w xhydrophobicity, as also shown by Fato et al. 42 in
their comparison between CoQ and DB. As pointed1
w xout by Degli Esposti et al. 93 , the bell-shaped
dependence of k rK on the hydrophobicity of thecat m
CoQ analogs resembles the bell-shaped dependence
of the inhibition constants for various Complex I
w xinhibitors 83,131,134–139 , reinforcing the idea that
chemically different classes of Complex I inhibitors
w xact as CoQ antagonists 93,98 .
Contrary to electron transfer, the rate of generation
of membrane potential, measured by use of the probe
oxonol VI, increased steadily with CoQ hydrophobic-
w xity 93 ; the energetic efficiency of Complex I with
respect to the entire respiratory chain was maximal
for quinones having more than nine carbons.
The proton pumping activity, studied by the extent
of fluorescence quenching of a pH-sensitive acridine
w xdye 133 , was also consistent with the presence of
two sites of interaction of CoQ analogs with the
Complex, both of which are rotenone-sensitive. One
site, which is more hydrophobic and interacts with
CoQ analogs having more than six carbons at the 6
position, leads to a rapid proton pumping and a
stoichiometric consumption of NADH; another site
preferentially reacts with CoQ analogs having less
than six carbons, including CoQ ; this site drives a1
slow proton pumping activity associated with NADH
oxidation that is overstoichiometric to the reduced
quinone acceptor, the latter finding being interpreted
w xas redox cycling from an unstable semiquinone 133 .
Hydrophilic CoQ analogs also exhibit low respiratory
control ratios for their NADH CoQ reductase activity,
contrary to the hydrophobic analogs. On top of these
two sites is the nonphysiological interaction of the
most hydrophilic quinones with iron–sulfur clusters.
w xIn the studies quoted above 93,133 CoQ was1
found to belong to the group interacting in part with
( )G. LenazrBiochimica et Biophysica Acta 1364 1998 207–221218
the nonphysiological site; this contrasts with the abil-
ity of CoQ to support oxidative phosphorylation1
y w x qwith a P:2e ratio approaching 1 104,140 and H
translocation with a Hqr2ey ratio approaching 4
w x 141 . The differences in the systems employed e.g.,
extent of partition to the hydrophobic site due to
w x.membrane lipid concentration, cf. Ref. 105 may be
responsible for some of the differences, which are,
however, far from being explained. Moreover, the
role of endogenous CoQ is not well defined, and it10
is not clear how protein-bound quinone may interact
with the exogenous acceptors under different experi-
mental conditions. Table 3 synoptically summarizes
major properties of quinones as electron acceptors
from Complex I.
8. Role of endogenous ubiquinone
It was shown that endogenous CoQ accepts elec-1
trons directly from Complex I in pentane-extracted
mitochondria without the involvement of the CoQ
w xpool 96 ; the presence of tightly bound CoQ in10
w xComplex I 39,97 means, however, that exogenous
CoQ is likely to accept electrons from a site contain-
w xing the tightly bound CoQ molecules 42 . Unfortu-
nately, it seems difficult, using extraction and recon-
stitution procedures, to differentiate between endoge-
nous quinone belonging to the free pool and quinone
bound to the Complex.
w xIt was found 42 that V is the same in mito-max
chondria before CoQ extraction and in extracted mi-
tochondria containing no detectable CoQ: it is there-
fore likely that exogenous CoQ molecules substitute
 .for the endogenous CoQ in the binding site s and10
interact with additional exogenous molecules in place
of the CoQ pool. This behavior is also in agreement10
with the strong reversible increase of K for exoge-m
nous quinones upon removal of endogenous CoQ10
w x  .42,75,144 Table 4 . A simple interaction of the
exogenous quinone directly with a protein site in
place of the endogenous CoQ would exhibit compe-10
tition by endogenous CoQ or by CoQ upon re-10 10
constitution; this pattern is actually exhibited by suc-
cinate CoQ reductase where the K for exogenousm
w xquinone is decreased by CoQ extraction 116,141 .
The opposite behavior in the case of NADH CoQ
Table 4
Effect of endogenous ubiquinone on the kinetics of NADH–CoQ1
a w xreductase 42
y1 y1 .  .Particles V mmol min mg K mMmax m
SMP 1.1 22
bBHM 0.35 20
BHM lyophilised 0.19 25
cBHM extracted 0.21 56
BHM extractedqCoQ 0.21 2110
BHM extractedqCoQ 0.22 275
BHM extractedqCoQ 0.20 243
a w xSimilar qualitative behavior was shared by PB 42 and DB
 .unpublished .
b  .Bovine heart mitochondria frozen and thawed .
cNo detectable CoQ present.
reductase where the K for CoQ is increased bym 1
w xCoQ extraction 42,75,116,144 may be interpreted to
mean that the quinone active site is different when
the endogenous CoQ is removed. This effect would10
make it difficult to observe a possible competition.
The fact that CoQ is poorly reduced at center i of1
the bc complex is direct proof that endogenous1
CoQ is not an efficient competitive acceptor at the10
concentrations at which the exogenous quinone is
added. Assuming a K for CoQ of Complex I of 5m 10
mM in the lipids, and a K for CoQ of 10 mM inm 1
w xthe lipid phase 42 and using the actual membrane
concentrations of both quinones under the assay con-
 .ditions i.e., 50 mM CoQ and 5 mM CoQ it can1 10
be calculated that over 70% of the electrons are
channeled to reduce exogenous CoQ . The slight1
competition of CoQ with respect to CoQ , how-10 1
ever, is overwhelmed by the change of nature of the
binding site when CoQ is present, so that the K10 m
for the exogenous acceptor is actually decreased.
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